What Are the Side Effects of Stopping Azathioprine?

Stopping azathioprine does not produce classic drug-withdrawal symptoms like those associated with opioids or certain psychiatric medications. You will not experience physical dependence effects, tremors, or rebound anxiety. The primary risk of discontinuation is a return of the underlying disease the drug was controlling, whether that is inflammatory bowel disease, autoimmune hepatitis, lupus nephritis, or protection of a transplanted organ. How large that risk is, how quickly it materializes, and what else changes in your body after stopping depends heavily on your specific condition and how long you were in remission before discontinuation.

How Quickly Azathioprine Leaves Your System

Once you stop taking azathioprine, its active metabolites clear from your body relatively fast. The key metabolite that suppresses your immune system has a median elimination half-life of about seven days, meaning most of it is gone within a few weeks.¹ That is the chemical side of things. The immune system side is slower. Certain immune cell populations that were suppressed during treatment can take longer to bounce back, particularly T-cell clones that were actively dividing while you were on the drug. This lag means the full effects of stopping, both good and bad, do not happen overnight. Your immune system gradually wakes back up over weeks to months, which is why flares often appear weeks or months after the last pill rather than the next day.

Disease Flare Is the Main Concern

The overwhelming focus in the medical literature on azathioprine discontinuation is not about new symptoms that appear because you stopped a drug. It is about old symptoms that come back because the disease is no longer being held in check. This distinction matters: what you feel after stopping is usually the disease reasserting itself, not a pharmacological withdrawal reaction. The relapse risk, the timeline, and the severity vary considerably depending on why you were taking azathioprine in the first place.

Relapse Risk in Crohn’s Disease

In Crohn’s disease, the evidence consistently shows that stopping azathioprine raises the chance of a flare compared to staying on it. A meta-analysis pooling data from multiple studies found that continuing the drug significantly lowered the odds of relapse at six, twelve, and eighteen months after discontinuation.² In one controlled trial, about one in five patients who stopped azathioprine relapsed within eighteen months, compared to roughly one in twelve who stayed on it.³ Those numbers might sound reassuring if you are on the fence about stopping, since the majority of patients in both groups stayed in remission. But the relapse rate climbs over time, and a recent systematic review and meta-analysis estimated the overall relapse rate for Crohn’s patients who stopped at roughly a quarter, while ulcerative colitis patients fared worse at about 41%.⁴

Interestingly, one large retrospective study found that patients who stopped azathioprine specifically because they had achieved stable remission did far better than those who stopped for other reasons. Their risk of relapse was substantially lower, with about 89% remaining relapse-free after one year and 79% after two years.⁵ The takeaway is that the circumstances of stopping matter enormously. If your doctor is suggesting withdrawal because your disease has been quiet for years and your markers look good, that is a very different risk profile than stopping because of a side effect or because the drug was not working well.

Relapse Risk in Ulcerative Colitis

People with ulcerative colitis tend to face a somewhat higher relapse rate after stopping azathioprine compared to those with Crohn’s, although results from individual studies have varied. In one study tracking 237 patients, moderate-to-severe relapse rates at twelve months were actually higher in Crohn’s patients (23%) than ulcerative colitis patients (12%), but the gap narrowed by 24 months.⁶ The larger meta-analysis cited earlier, which pooled more data, found that overall relapse rates were higher in ulcerative colitis than Crohn’s.⁴ The discrepancy between studies likely reflects differences in how long patients had been in remission, how remission was defined, and what monitoring was used. For both conditions, elevated inflammatory markers at the time of withdrawal predicted a higher chance of relapse, as did shorter duration of azathioprine treatment before stopping.

Autoimmune Hepatitis Is a Higher-Stakes Situation

If you are taking azathioprine for autoimmune hepatitis, stopping carries a particularly steep relapse risk. One study found that about two-thirds of patients who withdrew from treatment experienced a relapse, and most of those relapses happened within the first year. Nearly half of the relapsing patients presented with an acute hepatitis attack, meaning a sharp spike in liver inflammation that required urgent re-treatment.⁷ A broader review of the evidence found relapse rates ranging from 25% to nearly 100% across different studies, with the wide range driven by how strictly researchers defined relapse and how long patients had been in remission before stopping.⁸ Factors linked to higher relapse risk included the absence of an identifiable trigger for the initial disease, having other autoimmune conditions alongside the hepatitis, and having elevated liver enzymes at the time of withdrawal.

The severity of autoimmune hepatitis relapses is what makes this condition different from, say, a Crohn’s flare. While a Crohn’s relapse often means a return of gut symptoms that can be managed by restarting treatment, an autoimmune hepatitis flare involves active liver damage. Repeated cycles of flare and re-treatment can lead to cumulative liver scarring. This is why many hepatologists are cautious about stopping azathioprine in autoimmune hepatitis, even after years of normal blood tests.

Lupus Nephritis and Other Autoimmune Diseases

For people taking azathioprine to manage lupus nephritis (kidney inflammation from lupus), stopping immunosuppression also carries a real relapse risk. In one study of 45 patients who discontinued immunosuppressive therapy, those who had been on azathioprine had a higher rate of disease flare compared to patients who had been on other immunosuppressants like mycophenolate.⁹ The numbers in that study were small, so it is hard to draw sweeping conclusions, but the direction is consistent with the general pattern: stopping azathioprine means the immune system regains its ability to attack whatever it was attacking before.

Azathioprine is also used in conditions like myasthenia gravis, vasculitis, and certain skin diseases. Published withdrawal data for these conditions are thinner than for IBD or autoimmune hepatitis, but the underlying logic is the same. If the disease was active enough to require immunosuppression, removing that suppression creates an opening for it to return.

Organ Transplant Recipients

In transplant medicine, azathioprine was historically a cornerstone of anti-rejection therapy before newer drugs became standard. The concern with stopping in transplant patients is graft rejection rather than disease flare. Long-term follow-up data from kidney transplant recipients who stopped azathioprine found that about 28% experienced a decline in kidney function, and this was more common in patients whose donor organ was a poor immunological match. However, overall graft survival remained comparable to a control group that stayed on the drug.¹⁰ Modern transplant protocols typically use different combinations of immunosuppressants, but the principle holds: any reduction in immune suppression after transplantation must be weighed carefully against rejection risk.

Positive Changes After Stopping

Not everything about stopping azathioprine is bad news. If you experienced side effects while on the drug, many of those will resolve after discontinuation. In a prospective study of over 250 patients on thiopurines, the most common side effects that led to stopping were nausea (affecting about 12% of patients) and vague symptoms like fatigue, headache, and muscle pain (about 8%).¹¹ These typically improve once the drug clears your system.

Liver problems caused by azathioprine are another area where stopping brings clear benefit. Case reports and case series consistently show that liver enzyme levels return to normal after the drug is discontinued, often within weeks.¹² Even in cases of severe drug-induced liver injury, stopping azathioprine led to progressive normalization of blood tests and clinical improvement.¹³ A larger study of thiopurine-induced liver injury confirmed that essentially all patients recovered clinically after discontinuation, with liver tests returning to normal in all but two cases at final follow-up.¹⁴

Low white blood cell counts, a well-known side effect of azathioprine, also recover after stopping. This is relevant to infection risk. While you are on azathioprine, your immune defenses are deliberately weakened, which is the whole point of the drug but also why it increases vulnerability to infections. After stopping, your white cell counts climb back toward normal, and that window of heightened infection susceptibility gradually closes.

What Happens When You Stop the Azathioprine in a Combination Regimen

Many people with Crohn’s disease or ulcerative colitis take azathioprine alongside a biologic drug like infliximab. The azathioprine in this combination serves a dual purpose: it helps control the disease directly and it reduces the chance your body will make antibodies against the biologic, which can cause the biologic to lose effectiveness over time. Stopping azathioprine while continuing the biologic removes that second layer of protection.

A study tracking patients who dropped azathioprine while staying on infliximab found that about 73% remained failure-free at their last follow-up, but the picture deteriorated over time. The probability of infliximab continuing to work dropped substantially by two years. Patients who had been on the combination for a shorter period, those with elevated inflammatory markers, and those with higher platelet counts were at greater risk of infliximab failure after azathioprine was removed.¹⁵ If you are considering stopping azathioprine but staying on a biologic, this interaction is worth discussing with your gastroenterologist, because losing the biologic can be harder to fix than restarting azathioprine.

How Doctors Monitor You After Stopping

Because the main risk of stopping is a disease flare that might not announce itself with obvious symptoms right away, monitoring after withdrawal is important. For inflammatory bowel disease, fecal calprotectin (a stool test that detects gut inflammation) has emerged as a useful early warning tool. In a study of IBD patients who stopped azathioprine while in deep remission, an elevated fecal calprotectin level was the only variable that significantly predicted later relapse in both Crohn’s and ulcerative colitis.¹⁶ For autoimmune hepatitis, regular blood tests tracking liver enzymes serve a similar function. The common thread is that early detection of rising inflammation allows treatment to be restarted before a full-blown flare develops.

Most physicians will schedule more frequent check-ups in the first year after stopping, since that is when the majority of relapses occur. For IBD, that often means blood work and stool tests every few months. For autoimmune hepatitis, liver function tests are typically checked at short intervals initially and then gradually spaced out if everything stays quiet. If you are stopping azathioprine, ask your doctor what the monitoring plan looks like and what symptoms should prompt an urgent call.

Factors That Predict Whether You Will Flare

Across conditions, several factors consistently appear as predictors of relapse after azathioprine withdrawal:

Duration of remission: The longer your disease has been completely quiet before stopping, the lower the chance of relapse. Patients who stopped after years of stable remission fared much better than those who stopped after shorter periods.⁵
Inflammatory markers at withdrawal: Elevated C-reactive protein at the time of stopping was linked to higher relapse rates across multiple studies.⁴
Mucosal healing: For IBD specifically, whether the intestinal lining had fully healed (not just symptom improvement) mattered. Absence of mucosal healing before stopping was associated with higher relapse rates.
Duration of treatment: Shorter courses of azathioprine before stopping correlated with worse outcomes, suggesting the drug needs time to achieve a more durable remission.

These predictors can help you and your doctor decide whether the timing is right for a withdrawal attempt. If your markers are all quiet and your endoscopy shows healed tissue, the odds are more in your favor than if you still have smoldering inflammation.

Can You Restart Azathioprine If Things Go Wrong

For most people, the answer is yes. The majority of patients who relapse after stopping can successfully restart azathioprine and regain control of their disease. In the study of 237 IBD patients who stopped thiopurines, those who relapsed and restarted treatment generally recaptured remission.⁶ This is an important piece of the decision-making puzzle: stopping azathioprine is not necessarily a one-way door. If a flare happens, you have not burned a bridge. That said, a severe flare that requires hospitalization or rescue therapy is not trivial, which is why careful patient selection and monitoring after withdrawal matter.

Pregnancy and the Decision to Stop

One of the most common reasons people ask about stopping azathioprine is pregnancy planning. The situation here is more nuanced than many patients expect. While azathioprine is classified as a drug that could theoretically pose risks during pregnancy, an increasing body of evidence from prospective studies suggests it is safe for the fetus.¹⁷ A study of IBD patients found that use of azathioprine during pregnancy was not associated with increased risk of congenital anomalies or neonatal adverse outcomes.¹⁸

The paradox is that stopping azathioprine before or during early pregnancy can itself create problems. A separate study found that women with IBD who reduced or stopped azathioprine around the time of pregnancy often ended up needing higher doses of corticosteroids later in pregnancy to manage flares, and these women had an increased risk of low birth weight and preterm delivery.¹⁹ In other words, the flare triggered by stopping azathioprine may pose a greater risk to the pregnancy than the drug itself. Current gastroenterology guidelines generally recommend continuing azathioprine during pregnancy if it is needed to maintain remission, rather than stopping it preemptively. This is a conversation to have with both your gastroenterologist and obstetrician well before conception.

How Stopping Affects Infection Risk and Blood Counts

While on azathioprine, your white blood cell counts are intentionally lowered, which is part of how the drug dampens immune activity. In a study of 161 episodes of low lymphocyte counts in IBD patients on azathioprine, about 23% were classified as severe. Among those with severe drops, about a third had their dose reduced and another third had the drug stopped entirely. Opportunistic infections were identified in roughly 5.5% of lymphopenic episodes, though the study found no clear link between the severity of the low counts and infection risk.²⁰

After stopping azathioprine, your blood counts gradually normalize and your susceptibility to these opportunistic infections declines. For people who were experiencing recurrent infections or persistently low white cell counts while on the drug, this is a tangible benefit of discontinuation. The recovery timeline aligns roughly with the drug’s pharmacokinetic clearance, meaning blood counts typically start improving within a few weeks, though full immune reconstitution takes longer.

1
PubMed. Pharmacokinetics and Immune Reconstitution Following Discontinuation of Thiopurine Analogues: Implications for Drug Withdrawal Strategies
2
PubMed. Relapse rate following azathioprine withdrawal in maintaining remission for Crohn’s disease: a meta-analysis
3
Gastroenterology. A Randomized, Double-Blind, Controlled Withdrawal Trial in Crohn’s Disease Patients in Long-term Remission on Azathioprine
4
PubMed Central. Relapse Rates and Predictors Following Azathioprine Withdrawal in Inflammatory Bowel Disease: A Systematic Review, Meta-Analysis, and Meta-Regression
5
PubMed Central. Azathioprine monotherapy withdrawal in inflammatory bowel diseases: A retrospective mono-centric study
6
PubMed Central. Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients
7
PubMed Central. Is there any predictor for relapse after treatment withdrawal in autoimmune hepatitis patients in the real life?
8
PubMed. Stopping immunosuppressive treatment in autoimmune hepatitis (AIH): Is it justified (and in whom and when)?
9
PubMed Central. Lupus Nephritis Outcomes after Stopping Immunosuppression
10
PubMed. Azathioprine withdrawal in renal transplant recipients. A long-term follow-up
11
PubMed. Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience
12
PubMed Central. Azathioprine-Induced Rapid Hepatotoxicity
13
PubMed Central. Severe azathioprine-induced liver injury 22 months after initiation of treatment
14
PubMed Central. Azathioprine and 6-Mercaptopurine Induced Liver Injury: Clinical Features and Outcomes
15
American Journal of Gastroenterology. Predictors of Infliximab Failure After Azathioprine Withdrawal in Crohn’s Disease Treated With Combination Therapy
16
Clinical Gastroenterology and Hepatology. Noninvasive Monitoring After Azathioprine Withdrawal in Patients With Inflammatory Bowel Disease in Deep Remission
17
PubMed Central. Safety of azathioprine use during pregnancy
18
Journal of Crohn’s and Colitis. The effects of azathioprine on birth outcomes in women with inflammatory bowel disease (IBD)
19
PubMed. Use of azathioprine and corticosteroids during pregnancy and birth outcome in women diagnosed with inflammatory bowel disease
20
PLOS ONE. The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease